tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matt Larew, 1 are a HOLD (100%).
Analyst Matt Larew, currently employed at WILLIAM BLAIR,
Matt Larew’s has documented 2 price targets and ratings displayed on 9 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on AMED, Amedisys at 30-Dec-2024.
Analyst best performing recommendations are on DNA (GINKGO BIOWORKS HOLDINGS).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell Since 23-Aug-2024
$5
$-3.09 (-38.20%)
$9
4 months 21 days ago
(12-Mar-2026)
2/5 (40%)
$-1.4 (-21.88%)
41
Buy Since 20-Sep-2024
$12
$3.91 (48.33%)
$12
6 months 25 days ago
(08-Jan-2026)
2/3 (66.67%)
$2.94 (32.45%)
101
Buy Since 02-Mar-2022
$3
$-2.93 (-49.41%)
$120
1 years 10 months 17 days ago
(17-Sep-2024)
0/4 (0%)
$-3.81 (-55.95%)
Sell Since 20-Aug-2024
$7
$-1.09 (-13.47%)
1 years 11 months 13 days ago
(20-Aug-2024)
1/1 (100%)
$-0.71 (-9.21%)
10
Hold Since 04-Oct-2022
$40
1 years 11 months 14 days ago
(20-Aug-2024)
0/3 (0%)
$5.48 (15.87%)
What Year was the first public recommendation made by Matt Larew?
